🧫 Michigan Testing Under Fire, Colorado Inversion Flags Rise, Ohio Hemp Drinks Head For The Exit

Built by a former cannabis regulator, Policy, Decoded helps operators read the policy terrain before it shifts beneath their feet.

Today’s edition starts in Michigan, where regulators are putting the testing layer under formal fire and signaling that lab integrity is no longer a quiet compliance issue. We also track Colorado’s growing inversion concerns in the vape category, Ohio’s fast-approaching hemp beverage cutoff, and the broader push in Washington to impose national THC caps that could either stabilize the market or quietly hollow it out.

Policy, Decoded is written daily by THC Group, where we advise operators, investors, trade groups, and governments on policy, regulatory, and political headaches that do not come with clean rules. This briefing is also supported by The Hybrid podcast. Want to hear former regulators talk policy, power, and culture without pretending any of it is simple? That’s the show.

🧪 Testing trust on the line
🥤 Hemp drinks hit the brakes
🧾 Supply chains under scrutiny

You can’t market your way around bad data.

📌 What Happened: Michigan regulators have filed a formal administrative complaint accusing Prism Triangle, one of the state’s larger marijuana testing laboratories, of manipulating pesticide testing data tied to vape cartridges. The allegations are technical and serious. Regulators say lab staff manually altered chromatogram peak integration during calibration checks in ways that made instruments appear properly calibrated when they were not, producing unreliable pesticide results on product that reached retail shelves. The complaint also alleges the use of an unapproved aspergillus testing method on multiple packages, bypassing validated procedures the lab was required to follow.

The state is seeking penalties that can include fines, license restrictions, suspension, or revocation. This is not a warning letter or a quiet corrective action. It is a public enforcement action aimed at the integrity of the testing lane.

💡 Why It Matters: This is obviously bigger than one lab, although the spotlight is most assuredly on Prism Triangle. The ripple, though, is going to impact policy beyond them, and most likely beyond Michigan.

Testing labs sit at the load-bearing point between public health promises and commercial reality. When a lab is accused of massaging calibration or methods, the risk spreads immediately. Brands that relied on those results face recall and reputation exposure they did not design for (but should have planned for). Regulators lose confidence in the paper trail that supports compliance decisions. Consumers lose trust in the safety story that keeps legalization politically durable.

Michigan has seen versions of this cycle, and so have other mature markets. Price compression pushes labs into volume and margin behavior. Margin behavior creates incentives to cut corners, and the corner that gets cut first is the one the average buyer cannot see. The industry pays for that twice, first in enforcement, then in public confidence.

Expect Michigan to tighten audits, method controls, and documentation expectations. Expect compliant labs to start selling defensibility as the product. Expect manufacturers to learn that cheap testing has an expensive second act.

🧪 Colorado Vape Tests Raise Hemp Inversion Flags

A joint investigation found signs that some vapes sold in Colorado’s licensed marijuana stores may include hemp-derived cannabinoids that state marijuana rules prohibit. Three of fourteen products tested showed markers consistent with substitution, which is enough to force a governance response even before the state comments. Inhalation is the category where consumers expect the highest standard, and inversion turns a controlled chain into a shell game. Colorado’s next move likely lives in verification mechanics, input documentation, shelf testing, and enforcement aimed at manufacturers first. The market consequence stays simple: make noncompliance expensive or the incentive stays upside down. (MJBizDaily)

💨 Vapes Take The Top Spot In California

California’s licensed market saw vapes pass flower as the top revenue category, and the crossover held through year end. This shift is structural, and it changes where regulation and brand risk concentrate. A vape-dominant market pulls hardware, additives, and product safety into the center of the policy conversation because one high-profile failure travels fast and contaminates the whole lane. Operators also feel the economics, since repeatable convenience tends to reward scale and disciplined manufacturing. California’s shrinkage story continues, and category mix shows where consumers still spend when wallets get tighter. (Cannabis Business Times)

🗳️ Florida Judge Forces Signature Count Transparency As Legalization Clock Runs Out

A Florida judge ordered the state to resume weekly updates of verified signature totals for Smart & Safe Florida after the count sat unchanged for weeks. The process posture matters because deadlines create leverage, and silence from the scoreboard fuels distrust on both sides. This order does not fix the campaign’s signature math, and it does force transparency back into the lane while appeals and challenges keep flying. Florida remains the biggest medical-only prize in the country, so procedural turbulence freezes planning and keeps capital in wait-and-see mode. When election administration starts looking strategic, the state inherits a legitimacy problem that lasts longer than any one petition cycle. (Cannabis Business Times)

🌿 Hemp Brands Push Congress Toward Caps And Guardrails

Hemp brands are backing a federal framework that would set national dosage caps, push standards toward FDA oversight, and squeeze out the worst chemistry in the shadows. The pitch is stability, and the risk is that low caps can operate like a soft ban that hands demand back to unregulated channels. The only version of this that works is enforceable, with real testing rules, labeling clarity, age-gating, and penalties that land on bad actors fast. Congress can buy the market time if it pairs dosage math with a transition plan that does not strand compliant businesses midstream. A federal lane that is predictable and policed beats fifty state improvisations that reward whoever games the definitions best. (Modern Retail)

🥤 DeWine Owns The Ohio Hemp Beverage Hit And Calls It A Known Risk

Gov. Mike DeWine is defending Ohio’s coming crackdown on intoxicating hemp beverages, telling businesses they sold a product that sat on very thin ice. Senate Bill 56 takes effect in mid March and sets THC limits low enough to function as a ban, and DeWine vetoed a temporary 5 milligram carveout that would have kept beverages legal through the end of 2026. His posture sends a market signal: Ohio frames this as consumer safety and enforcement first, with economic fallout treated as secondary. The tension is visible, with breweries investing in new lines while the state tightens the rules. If lawmakers reopen the issue, the hinge will be parity and guardrails that survive inspection and court scrutiny. (cleveland.com)

⚖️ Missouri Cannabis Companies Sue Smoke Shops Over THCA Hemp Flower

Missouri licensed cannabis companies are suing dozens of smoke shops over THCA flower, arguing the products function like marijuana while skipping the state’s licensing, testing, and tax regime. The suit is a market structure fight dressed in legal claims, with licensed businesses saying they are competing against a parallel retail system that carries lower costs and higher risk. Hemp nuance matters here: lawful CBD and compliant low dose products belong in a regulated lane, and THCA flower has become the litigation magnet because it tracks consumer demand for traditional flower while living in a definitional loophole. The strategic issue for the state is consistency, because uneven enforcement invites more gray-market buildout and more private lawsuits that turn judges into de facto regulators. If plaintiffs start winning injunctions, the next ripple is predictable: more aggressive state action, faster legislative pressure, and a scramble by retailers to pivot products and paperwork before the crackdown spreads. (Missouri Independent)

🌽 Indiana Doubles Down On Prohibition And Tightens The Hemp Lane

Indiana lawmakers are tightening hemp and THC rules while legalization bills keep getting treated as dead on arrival, even as neighboring states normalize regulated markets. The political posture aims to look tough on youth access and retail clutter without taking on taxation, enforcement priorities, or market design. That strategy carries a predictable cost, because when you squeeze the hemp lane and keep marijuana illegal, demand migrates toward the least visible channel and the state loses safety leverage. Businesses that want to comply are left chasing a moving target, and enforcement becomes a permanent workload without the benefits of regulation. This is a choice about control, and Indiana is choosing friction over visibility. (Indiana Capital Chronicle)

🧾 New York’s Seed To Sale Deadline Mostly Landed

Cannabis Wire reports that nearly all operational New York licensees met the seed-to-sale integration deadline, bringing basic compliance infrastructure online after the market already scaled. The first-order win is visibility, and the second-order pain is operational because inventory hygiene and POS gaps turn into holds and cash flow friction quickly. Track and trace will not solve inversion and diversion on its own, and it gives enforcement the first credible ledger to follow. The next phase exposes who built real controls and who relied on chaos and good luck. New York needed an instrument panel, and now it has one that makes excuses harder to sell. (Cannabis Wire)

🌲 Maine Caregivers Push Back On Medical Track And Trace

Maine is weighing contaminant testing and product tracking for medical cannabis, and the dispute is about sequencing and survival as much as safety. Supporters point to baseline public health expectations, and opponents warn that adult-use style infrastructure can crush small caregivers if it lands all at once. A workable lane looks like phased compliance, clear thresholds, and affordable testing options that do not turn medicine into a luxury good. Maine can raise standards and keep caregivers alive, and that requires patient implementation plus enforcement aimed at real risk. This is a policy maturity test that rewards competence in the details. (WABI)

🏷️ Schedule III Puts Cannabis Labels Under A Brighter Light

A packaging trade outlet is mapping what federal rescheduling would mean on the shop floor, and labels are where federal gravity shows up first. Schedule III raises risk around implied wellness language and soft medical suggestions, because FDA standards treat disease-related marketing as drug territory. Brands will feel it in copy review discipline, warning prominence, and hierarchy that rewards legibility and defensibility. Converters with regulated-market muscle gain leverage because change control and error prevention become commercial advantages. Packaging teams will be doing the hard work well before consumers notice any broad shift. (Label and Narrow Web)

🏛️ A New York License Pitch Turns Into A Federal Strategy Tell

Sen. Kirsten Gillibrand floated a blunt theory for winning over Donald Trump on federal legalization: give him a New York cannabis business license and let self-interest do the work. The comment landed because it exposes how thin the governing lane remains inside the GOP conference. Reform stays bottlenecked by internal incentives and leadership math more than public opinion. Operators keep modeling Schedule III cash flow and capital access while Washington keeps feeding speculation. Watch for paper, process, and commitments that change how agencies and capital behave. Viral quotes keep people entertained and rarely move a rulemaking calendar. (Marijuana Moment)

🧪 Roadside Saliva Tests Stay On The Legislative Agenda

Michigan backers are still pushing to authorize roadside oral-fluid screens as a preliminary tool in suspected drug-impaired driving stops. Supporters want speed and a field option beyond waiting on blood results, and civil liberties advocates keep pressing the key flaw: presence does not equal impairment. The fight will land on guardrails, admissibility, privacy, and training, because the first contested cases will set the tone for deployment. If lawmakers move forward, they will need clear limits that prevent the test from becoming a shortcut to weak cases. The public expects safety and fairness, and this is where sloppy policy creates both legal exposure and distrust. (Spartan Newsroom Capital News Service)

🚗 California Supreme Court Tightens Cannabis Open Container Standard

California’s Supreme Court ruled that loose cannabis crumbs or seeds in a car do not qualify as an open container violation and do not justify a vehicle search on that theory alone. The court drew a practical line: the cannabis must be a usable quantity, in imminently usable condition, and readily accessible. This trims a common pretext pathway and pushes policing back toward observable conduct. Defense counsel will press the ruling quickly in suppression motions, and police training will adjust because cases will get tossed otherwise. The downstream effect is quiet and real: fewer leverage stops and cleaner legal standards. (California Supreme Court)

💰 Michigan’s New Wholesale Tax Hits A Market Already Bleeding

Michigan’s new wholesale tax took effect January 1st and landed in a market already shaped by price compression and thin margins. That timing forces hard choices: absorb the hit, raise prices, or cut staffing and inventory while hoping customers stay loyal. The behavioral risk is real, because sudden price gaps push value shoppers toward unregulated alternatives. This accelerates consolidation since scale buys time and fragile operators run out of runway. Tax policy can fund oversight, and it can also pick winners, and Michigan’s structure rewards balance sheets that can take a punch. (WTOL)

⚖️ Connecticut Hemp Industry Says State Rules Pushed It To The Edge

Connecticut’s hemp sector is shrinking, and growers blame tightening rules alongside a consumer market now owned by adult-use cannabis. The state still needs a coherent lane that distinguishes lawful hemp commerce from intoxicating loopholes without regulating the entire category into extinction. A contracting grower base also limits supply chain development and pushes commerce toward out-of-state products. The next session should focus on clear product categories, enforceable standards, and a retail system that rewards disciplined compliance. Markets adapt to tough rules and they stall under a moving target. (CT Insider)

🔒 Privacy Class Actions Start Circling Cannabis Websites

Class action firms are increasingly targeting cannabis companies over tracking pixels and session replay tools that allegedly share sensitive consumer data with third parties. The exposure grows in medical markets where patient status and purchase behavior carry higher sensitivity and statutes have sharper teeth. The fix is straightforward and urgent: audit trackers, tighten consent, minimize collection, and force vendors to meet your standards rather than their defaults. Companies that treat this as a minor website issue learn it as a litigation budget issue. The first cases set the playbook, and the industry tends to pay for that lesson twice. (Mondaq)

🏥 New Mexico Poison Control Sees Rising Cannabis And Weight Loss Drug Calls

New Mexico’s poison control center reports more than 1,000 cannabis exposure calls since 2021, with most involving children under 12 and a high share requiring hospital evaluation. Legal access expands household presence, and household presence punishes casual storage and unclear dosing. The same center is seeing a surge in GLP-1 exposure calls tied to compounded or black-market products and dosing errors, which reinforces a broader consumer-safety lesson about guardrails and sourcing. Cannabis legitimacy gets built through boring disciplines: child-resistant storage, plain-language dosing, and adult habits that anticipate accidental ingestion. Public health systems will keep absorbing this risk until safer handling becomes a cultural norm, not a poster. (Santa Fe New Mexican)

🍺 Cannabis Drinks Get Pitched As A Harm Reduction Off Ramp For Alcohol

A small University at Buffalo study suggests some consumers report lower alcohol intake after adding cannabis beverages to their routines. The policy pressure comes next: lawmakers will get asked to treat low-dose drinks as a moderation product while also policing bad actors who want the same shelf space with sloppy formulations. The category earns credibility through consistency, dosing clarity, and age-gated channels that look like adult hospitality. It loses credibility when products lean on loopholes and dare regulators to react. Standards decide whether harm reduction becomes a durable argument or a short-lived headline. (Cannabis Equipment News)

🥃 Gen Z Still Barely Moves Alcohol Sales

New Circana data shows Gen Z represented about 4 percent of U.S. alcohol shoppers in the 52-week period ending December 28, 2025. That number matters because it punctures a storyline that treats the youngest legal buyers as the whole market. Cannabis beverage growth will come from conversion and moderation among older drinkers with established routines and purchasing power. Brands chasing the loudest narrative risk missing the customers who buy consistently and pay the bills. Consumer categories move on habit, and register data says habit still lives with Gen X and up. (Yahoo Finance)

🏥 Mississippi Moves Medical Cannabis Into Hospitals

Mississippi lawmakers approved a bill that would allow terminally ill medical cannabis patients to use cannabis in hospitals and hospice settings. This closes a narrow gap with meaningful human impact, because patients have been forced to stop a legal therapy upon admission. Hospitals will still control form factors and administration, and that is where liability and clinical governance will live. Programs mature when they handle edge cases with dignity and clear protocols. The work now is aligning patient access with staff training and institutional risk management in a federal environment that still drives caution. (Marijuana Moment)